A Phase II Trial of Dasatinib in Subjects with Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
This is a clinical trial of dasatinib that will be administered by mouth, which is investigational.
IRB Protocol #
NIKKI AYODEJI at (720)848-0701 or NIKKI.AYODEJI@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period(s) that can last as long as your cancer is not progressing, and you are not experiencing any unacceptable side effects. A follow up period will consist of phone contact and possible clinic visits. // Eligibility criteria include but are not limited to 18 years or older with cancer and have a certain cell mutation.Eligibility criteria include but are not limited to 18 years or older with cancer and have a certain cell mutation.